These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32561328)

  • 1. Transfusional iron overload in patients with myelodysplastic syndromes: A 10-year retrospective survey from a French general hospital.
    Bauduer F; Recanzone H
    Transfus Clin Biol; 2020 Aug; 27(3):128-132. PubMed ID: 32561328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusional iron overload in heavily transfused patients: Real-life data from a 10-year retrospective study of 611 cases managed in a French general hospital.
    Bauduer F; Recanzone H
    Transfus Clin Biol; 2022 Aug; 29(3):236-242. PubMed ID: 35476962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
    Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
    Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
    Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
    Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Iron overload and myelodysplastic syndromes].
    Rose C; Cambier N; Mahieu M; Ernst O; Fenaux P
    Transfus Clin Biol; 2001 Oct; 8(5):422-32. PubMed ID: 11729396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
    Wong CAC; Wong SAY; Leitch HA
    Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
    Jabbour E; Garcia-Manero G; Taher A; Kantarjian HM
    Oncologist; 2009 May; 14(5):489-96. PubMed ID: 19365094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron overload in myelodysplastic syndromes: diagnosis and management.
    List AF
    Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
    Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
    Angelucci E; Li J; Greenberg P; Wu D; Hou M; Montano Figueroa EH; Rodriguez MG; Dong X; Ghosh J; Izquierdo M; Garcia-Manero G;
    Ann Intern Med; 2020 Apr; 172(8):513-522. PubMed ID: 32203980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
    Leitch HA; Gattermann N
    Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
    Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
    Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes: A Study by the Israeli MDS Working Group.
    Merkel D; Soffer S; Filanovsky K; Braester A; Fibach E; Dana M; Ofran Y; Greenbaum U; Nagler A; Amitai I; Mittelman M
    Acta Haematol; 2024; 147(4):427-434. PubMed ID: 38104534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transfusions in myelodysplastic syndromes].
    Rose C
    Transfus Clin Biol; 2017 Sep; 24(3):209-215. PubMed ID: 28651884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C; Clissa C; Stanzani M
    Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.